Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 3 , Pages 209-217, September 2005

Mechanisms Involved in Chemoresistance in Ovarian Cancer

  • Fu-Shing Liu

      Affiliations

    • Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr. Fu-Shing Liu, Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, 160, Section 3, Chung-Kang Road, Taichung, Taiwan

Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, Taichung, Taiwan

Received 11 July 2005; received in revised form 13 July 2005; accepted 14 July 2005.

Article Outline

Summary

Chemotherapy is a major treatment modality for ovarian cancer, but chemoresistance is a clinical problem that compromises the efficiency of treatment and finally results in treatment failure. The development of resistance to chemotherapeutic agents might be related to multiple mechanisms such as alterations in drug transport, changes in cellular proteins involved in detoxification, altered drug target, changes in DNA repair mechanisms, and increased tolerance to drug-induced DNA damage. This article is a summary of the various mechanisms that are involved in chemoresistance in ovarian cancer.

Key Words:  chemoresistance , chemotherapy , ovarian cancer

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. McGuire WP , Ozols RF . Chemotherapy of advanced ovarian cancer . Semin Oncol . 1998;25:340–348
  2. Ozols R . Treatment of gynecologic cancer: the US experience . Tumori . 1999;85:S5–11
  3. el-Deiry WS . Role of oncogenes in resistance and killing by cancer therapeutic agents . Curr Opin Oncol . 1997;9:79–87
  4. Gottesman MM , Fojo T , Bates SE . Multidrug resistance in cancer: role of ATP-dependent transporters . Nat Rev Cancer . 2002;2:48–58
  5. Joncourt F , Buser K , Altermatt H , Bacchi M , Oberli A , Cerny T . Multiple drug resistance parameter expression in ovarian cancer . Gynecol Oncol . 1998;70:176–182
  6. Perek N , Denoyer D . The multidrug resistance mechanisms and their interactions with the radiopharmaceutical probes used for an in vivo detection . Curr Drug Metab . 2002;3:97–113
  7. Grant CE , Kurz EU , Cole SP , Deeley RG . Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA . Genomics . 1997;45:368–378
  8. Cole SP , Bhardwaj G , Gerlach JH , et al.   Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line . Science . 1992;258:1650–1654
  9. Zaman GJ , Versantvoort CH , Smit JJ , et al.   Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines . Cancer Res . 1993;53:1747–1750
  10. Schneider E , Horton JK , Yang CH , Nakagawa M , Cowan KH . Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance . Cancer Res . 1994;54:152–158
  11. Zaman GJ , Flens MJ , van Leusden MR , et al.   The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump . Proc Natl Acad Sci USA . 1994;91:8822–8826
  12. Grant CE , Valdimarsson G , Hipfner DR , Almquist KC , Cole SP , Deeley RG . Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs . Cancer Res . 1994;54:357–361
  13. Cole SP , Sparks KE , Fraser K , et al.   Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells . Cancer Res . 1994;54:5902–5910
  14. He X , Ee PL , Coon JS , Beck WT . Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20 . Clin Cancer Res . 2004;10:4652–4660
  15. Seiden MV , Swenerton KD , Matulonis U , et al.   A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy . Gynecol Oncol . 2002;86:302–310
  16. Chaudhary PM , Roninson IB . Activation of MDR1 (P- glycoprotein) gene expression in human cells by protein kinase C agonists . Oncol Res . 1992;4:281–290
  17. Hannon GJ . RNA interference . Nature . 2002;418:244–251
  18. Fjose A , Ellingsen S , Wargelius A , Seo HC . RNA interference: mechanisms and applications . Biotechnol Annu Rev . 2001;7:31–57
  19. Duan Z , Brakora KA , Seiden MV . Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells . Mol Cancer Ther . 2004;3:833–838
  20. Wu H , Hait WN , Yang JM . Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells . Cancer Res . 2003;63:1515–1519
  21. Rebbeck TR . Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility . Cancer Epidemiol Biomarkers Prev . 1997;6:733–743
  22. Blackburn AC , Woollatt E , Sutherland GR , Board PG . Characterization and chromosome location of the gene GSTZ1 encoding the human zeta class glutathione transferase and maleylacetoacetate isomerase . Cytogenet Cell Genet . 1998;83:109–114
  23. Board PG , Coggan M , Chelvanayagam G , et al.   Identification, characterization, and crystal structure of the omega class glutathione transferases . J Biol Chem . 2000;275:24798–24806
  24. Lewis AD , Hayes JD , Wolf CR . Glutathione and glutathione dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects . Carcinogenesis . 1988;9:1283–1287
  25. Smith M , Evans C , Doane-Setzer P , Castro V . Denitrosation of 1,3 bis (2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells . Cancer Res . 1989;49:2621–2625
  26. Black SM , Beggs JD , Hayes JD , Murarratsu M , Sakai M , Wolfe CR . Expression of human glutathione S-transferase in S. cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil . Biochem J . 1990;268:309–315
  27. Coughlin SS , Hall IJ . Glutathione S-transferase polymorphisms and risk of ovarian cancer: a huge review . Genet Med . 2002;4:250–257
  28. Ferrandina G , Scambia G , Damia G , et al.   Glutathione S- transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome . Ann Oncol . 1997;8:343–350
  29. Sarhanis P , Redman C , Perrett C , et al.   Epithelial ovarian cancer: influence of polymorphism at the glutathione S- transferase GSTM1 and GSTT1 loci on p53 expression . Br J Cancer . 1996;74:1757–1761
  30. Green JA , Robertson LJ , Clark AH . Glutathione S-transferase expression in benign and malignant ovarian tumors . Br J Cancer . 1993;68:235–239
  31. Cherian MG , Jayasurya A , Bay BH . Metallothioneins in human tumors and potential roles in carcinogenesis . Mutat Res . 2003;533:201–209
  32. Jordan MA , Toso RJ , Thrower D , Wilson L . Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations . Proc Natl Acad Sci USA . 1993;90:9552–9556
  33. Kavallaris M , Kuo DY , Burkhart CA , et al.   Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes . J Clin Invest . 1997;100:1282–1293
  34. Giannakakou P , Sackett DL , Kang YK , et al.   Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization . J Biol Chem . 1997;272:17118–17125
  35. Monzo M , Rosell R , Sanchez JJ , et al.   Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations . J Clin Oncol . 1999;17:1786–1793
  36. Tsurutani J , Komiya T , Uejima H , et al.   Mutational analysis of the beta-tubulin gene in lung cancer . Lung Cancer . 2002;35:11–16
  37. Sale S , Sung R , Shen P , et al.   Conservation of the class I {beta}-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers . Mol Cancer Ther . 2002;1:215–225
  38. Nicoletti MI , Valoti G , Giannakakou P , et al.   Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents . Clin Cancer Res . 2001;7:2912–2922
  39. Holden JA . Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs . Ann Clin Lab Science . 1997;27:402–411
  40. Guinee DG , Holden JA , Benfield JR , et al.   Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response . Cancer . 1996;78:729–735
  41. Lynch BJ , Guinee DG , Holden JA . Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer . Hum Pathol . 1997;28:1180–1188
  42. Iino K, Sasano H, Yabuki N, Oki Y, Kikuchi A, Yoshimi T, et al. DNA topoisomerase II and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas . Mod Pathol . 1997;10:901–907
  43. Kellner U , Sehested M , Jensen P , et al.   Culprit and victim-DNA topoisomerase II . Lancet Oncol . 2002;3:235–243
  44. Pommier Y . DNA topoisomerase I and II in cancer chemotherapy: update and perspectives . Cancer Chemother Pharmacol . 1993;32:103–108
  45. Masuda H , Tanaka T , Matsuda H , Kusaba I . Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum (II) . Cancer Res . 1990;50:1863–1866
  46. Parker RJ , Eastman A , Bostick-Bruton F , Reed E . Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation . J Clin Invest . 1991;87:772–777
  47. Zhen W , Link CJ , O'Connor PM , et al.   Increased genespecific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines . Mol Cell Biol . 1992;12:3689–3698
  48. Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines . Biochem Pharmacol . 1994;47:689–697
  49. Ferry KV , Hamilton TC , Johnson SW . Increased nucleotide excision repair in cisplatin resistant ovarian cancer cells . Biochem Pharmacol . 2000;60:1305–1313
  50. Wood RD . Nucleotide excision repair in mammalian cells . J Biol Chem . 1997;272:23465–23468
  51. Fraser M , Leung B , Jahani-Asl A , Yan X , Thompson WE , Tsang BK . Chemoresistance in human ovarian cancer: the role of apoptotic regulators . Reprod Biol Endocrinol . 2003;1:66
  52. Yuan ZQ , Sun M , Feldman RI , et al.   Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer . Oncogene . 2000;19:2324–2330
  53. Lasky T , Silbergeld E . P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers . Environ Health Perspect . 1996;104:1324–1331
  54. Gatti L , Supino R , Perego P , et al.   Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response . Cell Death Differ . 2002;9:1352–1359
  55. Servidei T , Ferlini C , Riccardi A , et al.   The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin . Eur J Cancer . 2001;37:930–938
  56. Schneiderman D , Kim J-M , Senterman M , Tsang BK . Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells . Apoptosis . 1999;4:271–282
  57. Li J , Feng Q , Kim JM , et al.   Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins . Endocrinology . 2001;142:370–380
  58. Mansouri A , Zhang Q , Ridgway LD , Tian L , Claret FX . Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation . Oncol Res . 2003;13:399–404
  59. Robertson JD , Orrenius S , Zhivotovsky B . Review: nuclear events in apoptosis . J Struct Biol . 2000;129:346–358
  60. Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin SA, Zamzami N, et al. Apoptosis inducing factor: an ubiquitous mitochondrial oxidoreductase involved in apoptosis regulation . FEBS Lett . 2000;476:118–123
  61. Ahn HJ , Kim YS , Kim JU , Han SM , Shin JW , Yang HO . Mechanism of Taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells . J Cellular Biochem . 2004;91:1043–1052
  62. Jesenberger V , Jentsch S . Deadly encounter: ubiquitin meets apoptosis . Nat Rev Mol Cell Biol . 2002;3:112–121
  63. Verhagen AM , Coulson EJ , Vaux DL . Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs . Genome Biol . 2001;2:3009; 1-reviews3009.10.
  64. Deveraux QL , Takahashi R , Salvesen GS , Reed JC . X-linked IAP is a direct inhibitor of cell-death proteases . Nature . 1997;388:300–304
  65. Sasaki H , Sheng Y , Kotsuji F , Tsang BK . Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells . Cancer Res . 2000;60:5659–5666
  66. Krammer PH . CD95's deadly mission in the immune system . Nature . 2000;407:789–795
  67. Meng Y , Kang S , So J , Reierstad S , Fishman DA . Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis . Gynecol Oncol . 2005;96:462–469
  68. Ashkenazi A , Dixit VM . Death receptors: signaling and modulation . Science . 1998;281:1305–1308
  69. Uslu R , Jewett A , Bonavida B . Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis . Gynecol Oncol . 1996;62:282–291
  70. Irmler M , Thome M , Hahne M , et al.   Inhibition of death receptor signals by cellular FLIP . Nature . 1997;388:190–195
  71. Srinivasula SM , Ahmad M , Lin JH , et al.   CLAP, a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway, regulates NF-kappaB activation and apoptosis . J Biol Chem . 1999;274:17946–17954
  72. Hassan MI , Kassim SK , Saeda L , Laban M , Khalifa A . Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue . Anticancer Res . 1999;19:5657–5662
  73. Naylor MS , Stamp GW , Foulkes WD , Eccles D , Balkwill FR . Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression . J Clin Invest . 1993;91:2194–2206
  74. Xiao CW , Yan X , Li Y , Reddy SA , Tsang BK . Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein . Endocrinology . 2003;144:623–630
  75. Mezzanzanica D , Balladore E , Turatti F , et al.   CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma . Clin Cancer Res . 2004;10:5202–5214
  76. Samanta AK , Huang HJ , Bast RC , Liao WS . Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB . J Biol Chem . 2004;279:7576–7583
  77. Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, et al. Role of X-linked inhibitor of apoptosis protein in chemo-resistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway . Drug Resist Updat . 2002;5:131–146
  78. Philp AJ , Campbell IG , Leet C , et al.   The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors . Cancer Res . 2001;61:7426–7429
  79. Fraser M , Leung BM , Yan X , Dan HC , Cheng JQ , Tsang BK . P53 is a determinant of Xiap/Akt-mediated chemoresistance in human ovarian cancer cells . Cancer Res . 2003;63:7081–7088
  80. Yuan ZQ , Feldman RI , Sussman GE , Coppola D , Nicosia SV , Cheng JQ . AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance . J Biol Chem . 2003;278:23432–23440
  81. Asselin E , Mills GB , Tsang BK . XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells . Cancer Res . 2001;61:1862–1868
  82. Brinkmann U , Brinkmann E , Gallo M , Scherf U , Pastan I . Role of CAS, human homologue to the yeast chromosome segregation gene CSE, in toxin and TNF mediated apoptosis . Biochemistry . 1996;35:6981–6999
  83. Brustmann H . Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study . Gynecol Oncol . 2004;92:268–276
  84. Ioffe OB , Papadimitriou JC , Drachenberg CB . Correlation of proliferative indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium . Hum Pathol . 1998;29:1150–1159
  85. Krajewski S , Krajewska M , Shabaik A , et al.   Immunohisto-chemical analysis of in vivo patterns of bcl-x expression . Cancer Res . 1994;54:5501–5507
  86. Reed JC . Dysregulation of apoptosis in cancer . J Clin Oncol . 1999;17:2941–2953
  87. Yang X , Zheng F , Xing H , et al.   Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer . J Cancer Res Clin Oncol . 2004;130:423–428
  88. Vogelstein B , Lane D , Levine AJ . Surfing the p53 network . Nature . 2000;408:307–310

PII: S1028-4559(09)60143-1

doi:10.1016/S1028-4559(09)60143-1

Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 3 , Pages 209-217, September 2005

Article Tools